|
Polymorphisms
|
HAM/TSP
|
AC
|
Crude
| | |
|---|
|
n (%)
|
n (%)
|
OR (IC:95%)
|
p-value
|
Corrected p-value
|
|---|
|
IL10-1082G/A
|
|
A/A (low)
|
20 (32.3)
|
38 (53.5)
|
1
| | |
|
G/A (intermediate)
|
34 (54.8)
|
24 (33.8)
|
2.69 (1.28–5.79)
| | |
|
G/G (high)
|
8 (12.9)
|
9 (12.7)
|
1.69 (0.56–5.1)
|
0.07
|
0.21
|
|
A/A
|
20 (32.3)
|
38 (53.5)
|
1
| | |
|
G/A G/G
|
42 (67.7)
|
33 (46.5)
|
2.42 (1.2–4.97)
|
0.01
|
0.07
|
|
Alleles
|
|
A
|
74 (59.7)
|
100 (70.4)
|
1
| | |
|
G
|
50 (40.3)
|
42 (29.6)
|
1.61 (0.97–2.70)
|
0.07
|
0.21
|
|
IL10–819/−592
a
|
|
C/C and C/C
|
25 (43.3)
|
29 (40.8)
|
1
| | |
|
C/T and C/A
|
31 (50.0)
|
27 (38.0)
|
1.33 (0.63–2.8)
| | |
|
T/T and A/A
|
6 (9.7)
|
15 (21.2)
|
0.46 (0.15–1.33)
|
0.38
|
1
|
|
C/C and C/C
|
25 (40.3)
|
29 (40.8)
|
1
| | |
|
C/T + T/T and C/A + A/A
|
37 (59.7)
|
42 (59.2)
|
1.02 (0.51–2.05)
|
1
|
1
|
|
T/T and A/A
|
6 (9.7)
|
15 (21.2)
|
1
| | |
|
C/C + C/T and C/C + C/A
|
56 (90.3)
|
56 (78.8)
|
2.5 (0.94–7.44)
|
0.12
|
0.84
|
|
Phenotype
|
|
ACC/ACC, ACC/ATA, ATA/ATA (Low)
|
20 (32.3)
|
38 (53.5)
|
1
| | |
|
GCC/ACC, GCC/ATA (Intermediate)
|
34 (54.8)
|
24 (33.8)
|
2.69 (1.28–5.79)
| | |
|
GCC/GCC (High)
|
8 (12.9)
|
9 (12.7)
|
1.69 (0.56–5.10)
|
0.07
|
0.21
|
- HAM/TSP HTLV-1 associated myelopathy tropical spastic paraparesis, Asymptomatic HTLV-1 patients, OR odds ration with confident interval, Chi-square 2 × 2 or 3 × 2 contingent tables, Fisher exact or Cochran-Armitage tests
- a-819 and -592 are in linkage disequilibrium
